Laurence Mandereau-Bruno1, Damien Léger2, Marie-Christine Delmas1. 1. Santé Publique France, The French National Public Health Agency, Saint-Maurice, France. 2. EA 7330 VIFASOM and APHP-Hôtel Dieu, Centre du Sommeil et de la Vigilance, Université de Paris, Paris, France.
Abstract
INTRODUCTION: Obstructive sleep apnea (OSA) is a frequent condition. In the absence of treatment, OSA is associated with a higher risk of traffic accidents and a large variety of diseases. The objectives of this study were to describe the characteristics of patients treated for OSA in France and assess the time trends in treatment. METHODS: The French National Health Data System is an individual database with data on all healthcare reimbursements for the entire French population. Based on this database, we included all patients aged 20 years or over who were treated with continuous positive airway pressure (CPAP) or mandibular advancement splint (MAS) between 2009 and 2018. Negative binomial models, adjusted for age, were used to assess time trends in treatment prevalence and incidence rates. RESULTS: In 2017, 2.3% of French adults aged ≥20 years were treated with CPAP (men: 3.3%; women: 1.3%). The highest prevalence was observed in people aged 70-74 years (5.0%). From 2009 to 2018, the annual prevalence of CPAP increased 3-fold and the annual incidence 1.9-fold. During the same period, the rate of patients reimbursed for MAS (first prescription or renewal) was multiplied by 7.6. The proportion of patients treated with CPAP in 2017 who were no longer treated in the subsequent year was 6.9%. DISCUSSION: The sharp increase in the incidence of OSA treatment probably reflects a better recognition of the disease in France. However, the prevalence of OSA treatment remains lower than expected based on the international literature. Further studies are needed to identify the obstacles to an optimal management of individuals with OSA in France.
INTRODUCTION:Obstructive sleep apnea (OSA) is a frequent condition. In the absence of treatment, OSA is associated with a higher risk of traffic accidents and a large variety of diseases. The objectives of this study were to describe the characteristics of patients treated for OSA in France and assess the time trends in treatment. METHODS: The French National Health Data System is an individual database with data on all healthcare reimbursements for the entire French population. Based on this database, we included all patients aged 20 years or over who were treated with continuous positive airway pressure (CPAP) or mandibular advancement splint (MAS) between 2009 and 2018. Negative binomial models, adjusted for age, were used to assess time trends in treatment prevalence and incidence rates. RESULTS: In 2017, 2.3% of French adults aged ≥20 years were treated with CPAP (men: 3.3%; women: 1.3%). The highest prevalence was observed in people aged 70-74 years (5.0%). From 2009 to 2018, the annual prevalence of CPAP increased 3-fold and the annual incidence 1.9-fold. During the same period, the rate of patients reimbursed for MAS (first prescription or renewal) was multiplied by 7.6. The proportion of patients treated with CPAP in 2017 who were no longer treated in the subsequent year was 6.9%. DISCUSSION: The sharp increase in the incidence of OSA treatment probably reflects a better recognition of the disease in France. However, the prevalence of OSA treatment remains lower than expected based on the international literature. Further studies are needed to identify the obstacles to an optimal management of individuals with OSA in France.
Authors: S Fuentes; L Mandereau-Bruno; N Regnault; P Bernillon; C Bonaldi; E Cosson; S Fosse-Edorh Journal: Diabetes Metab Date: 2020-01-07 Impact factor: 6.041
Authors: E O Bixler; A N Vgontzas; H M Lin; T Ten Have; J Rein; A Vela-Bueno; A Kales Journal: Am J Respir Crit Care Med Date: 2001-03 Impact factor: 21.405
Authors: Shahrokh Javaheri; Ferran Barbe; Francisco Campos-Rodriguez; Jerome A Dempsey; Rami Khayat; Sogol Javaheri; Atul Malhotra; Miguel A Martinez-Garcia; Reena Mehra; Allan I Pack; Vsevolod Y Polotsky; Susan Redline; Virend K Somers Journal: J Am Coll Cardiol Date: 2017-02-21 Impact factor: 24.094
Authors: Terry Young; Eyal Shahar; F Javier Nieto; Susan Redline; Anne B Newman; Daniel J Gottlieb; Joyce A Walsleben; Laurel Finn; Paul Enright; Jonathan M Samet Journal: Arch Intern Med Date: 2002-04-22
Authors: Katrina Giskes; Frank J van Lenthe; Gavin Turrell; Carlijn B M Kamphuis; Johannes Brug; Johan P Mackenbach Journal: Obesity (Silver Spring) Date: 2008-03-20 Impact factor: 5.002